Saxenda for weight loss: separating real data from TikTok hype

What did @summerthedietitian actually say?

The creator gave a pretty low-stakes community-building video about liraglutide (Saxenda), inviting viewers to share their experiences. The substantive claims were brief: Saxenda is "one of the older medications," it's a "daily injectable," insurance coverage is improving, supply shortages are less severe than with semaglutide, and people struggling to access Wegovy "are starting their GLP-1 journey on Saxenda." No dosing advice, no cure claims, just orientation.

That's worth noting up front. A lot of GLP-1 content on TikTok is either hype or fear. This was neither. It was a dietitian trying to build a support community for people on a drug that gets less airtime than Ozempic or Mounjaro. The clinical claims are sparse enough that most of this fact-check is about filling in what wasn't said rather than correcting errors.

Does the science back this up?

Yes, mostly. The core claims hold. Saxenda (liraglutide 3.0 mg) has been FDA-approved for chronic weight management since 2014, making it genuinely older than semaglutide-based options. The daily injection requirement is accurate. And supply data supports the shortage comparison.

On efficacy, the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed liraglutide 3.0 mg produced about 8 percent mean body weight loss versus 2.6 percent for placebo at 56 weeks. That's meaningful, but it's lower than what STEP 1 (Wilding et al., 2021, NEJM) showed for semaglutide 2.4 mg: roughly 14.9 percent weight loss. The creator didn't make a comparative efficacy claim, which was smart, but viewers switching from Wegovy to Saxenda for access reasons should understand these drugs are not interchangeable in terms of outcomes.

On insurance coverage improving for Saxenda, this is consistent with recent formulary trends as manufacturers negotiate, though coverage remains highly plan-dependent.

What did they get wrong (or right)?

The creator got the basics right. Saxenda is older, it is a daily injectable, and it does face fewer supply disruptions than Wegovy. Credit where it's due.

The one thing that could have used more precision: framing Saxenda as a place to "start your GLP-1 journey" while waiting for Wegovy access glosses over the fact that liraglutide and semaglutide are different molecules with different efficacy profiles. They're both GLP-1 receptor agonists, but treating one as a placeholder for the other can set unrealistic expectations. Someone who loses 7 percent on Saxenda and then switches to Wegovy may see more loss, or they may not, and the transition isn't automatic or seamless.

There's also no mention of the side effect profile. Nausea, vomiting, and gastrointestinal distress are common with liraglutide, and the daily injection schedule can affect adherence. Davies et al. (2015, Diabetes Care) noted GI events were the most frequent adverse effects in liraglutide trials. Not mentioning this in a community-building video isn't a factual error, but it's a gap.

What should you actually know?

If you're on Saxenda or considering it, a few things matter that this video didn't cover. First, efficacy is real but more modest than newer GLP-1 agents. Second, the daily injection burden is higher than weekly semaglutide or tirzepatide, and adherence studies suggest this matters: Romera et al. (2010, Patient Preference and Adherence) found injection frequency affects long-term compliance in injectable therapies. Third, insurance coverage for Saxenda varies widely by plan and indication, and "improving" coverage still doesn't mean your plan covers it.

Fourth, and this is the part most social media GLP-1 content skips: stopping any GLP-1 medication without a medical plan typically leads to weight regain. Wilding et al. (2022, Diabetes, Obesity and Metabolism) documented significant rebound after semaglutide discontinuation, and similar patterns are expected with liraglutide. A community of people sharing experiences is genuinely valuable, but it's not a substitute for ongoing clinical supervision.